Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydroxyethylcellulose (HEC) gel is a pharmacologically inert, isotonic hydrogel derived from cellulose. In the context of HIV prevention research, it is widely utilized as the "universal placebo" in clinical trials for topical microbicides. Developed to be chemically stable and non-toxic to vaginal flora and the epithelial lining, it serves as a standardized control to evaluate the safety and efficacy of active microbicidal agents. Biosyn and other developers have employed HEC gel in Phase 1 imaging studies using enhanced MRI techniques to characterize the vaginal distribution, coverage, and retention of topical formulations before and after simulated coitus, providing critical data for the optimization of drug delivery systems in the female reproductive tract.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydroxyethylcellulose gel.